Development of dense gas technology platforms for the formulation of oral vaccines. This project will aim to develop a technology platform that enables the formulation of vaccines that can be delivered orally and this research has the potential to radically change existing vaccination regimens. The availability of needle-free vaccination also has potential for considerable societal and economic impact in developing countries.
Utilisation of dense gas technology for the development of controlled release active pharmaceutical ingredients (API) delivery systems. The aim of this project is to develop an orally administered drug formulation for the treatment of irritable bowel syndrome and other diseases of the colon. Irritable bowel syndrome is a debilitating condition and the cost to society is similar to that of asthma. As such, the project has the potential to have a major impact on society.
Highly multiplexed rapid-analysis microarrays for early disease diagnosis. Molecular diagnostics are revolutionising the treatment of disease in hospitals by providing rapid and accurate identification of pathogens; saving costs, time and lives. This project will accelerate this revolution by combining new array technology from the University of Sydney with a proven multiplex method from the Sydney based company, AusDiagnostics.
Magnetically controlled drug release from tissue scaffolds for the treatment of acute burns. Severe skin burns are frequently associated with functionally disabling scarring and the risk of death. New magnetically activated wound seals for the treatment of acute burns will be developed that reduce the need for frequent painful dressing changes and hence facilitate rapid healing with a significantly reduced chance of scarring.
Broad spectrum nanomedicine for Meningitis treatment. Brain inflammatory diseases are among the top ten infectious causes of death. The project aims to provide Australian doctors with a superior alternative of treating infections that do not respond to conventional antibiotics. The nanomedicine developed will reduce the burden of hospital and boost Australia economy in the biomedical sector.
Discovery Early Career Researcher Award - Grant ID: DE140101553
Funder
Australian Research Council
Funding Amount
$395,220.00
Summary
A flexible virus-like particle delivery platform for next-generation vaccines. Murine polyomavirus (MPyV) capsid proteins self-assemble into spherical protein shells approximately 45 nm in diameter. Such virus-like particles (VLPs) are of considerable interest as bionanotechnological tools. The unique flexibility provided by MPyV VLPs will be exploited by exploring the ability of the interior cavity to retain bioactive cargos while engineering novel functionality on the exterior surface by 'mix- ....A flexible virus-like particle delivery platform for next-generation vaccines. Murine polyomavirus (MPyV) capsid proteins self-assemble into spherical protein shells approximately 45 nm in diameter. Such virus-like particles (VLPs) are of considerable interest as bionanotechnological tools. The unique flexibility provided by MPyV VLPs will be exploited by exploring the ability of the interior cavity to retain bioactive cargos while engineering novel functionality on the exterior surface by 'mix-and-match' assembly of VLPs from modified components. As a proof of concept for next-generation vaccines that stimulate much needed, broadly protective responses against infectious diseases, model antigens will be delivered to specific immune cells using this nano-container.Read moreRead less
Treating tuberculosis: targeted delivery of multidrug nano-suspensions. Tuberculosis (TB) is a lung disease of worldwide prevalence. Treatment times are long and mortality is high in children and the elderly. Current treatments are ineffective and drug resistant TB is a real pandemic threat. The project will develop a cost-effective nano-particle system that can be incorporated into conventional nebulisers for use worldwide.
Nanoparticles to combat cellular dysfunction. This project aims to design, synthesise and characterise nanoparticles that can mediate the adverse effects of reactive oxygen species. The project expects to develop nanoparticles with tailored chemical functionality to modulate the concentration of reactive oxygen species and develop a platform technology for addressing conditions where reactive species are overproduced. The project will research how nanoparticles’ physicochemical properties affect ....Nanoparticles to combat cellular dysfunction. This project aims to design, synthesise and characterise nanoparticles that can mediate the adverse effects of reactive oxygen species. The project expects to develop nanoparticles with tailored chemical functionality to modulate the concentration of reactive oxygen species and develop a platform technology for addressing conditions where reactive species are overproduced. The project will research how nanoparticles’ physicochemical properties affect their activity, and how they affect cellular function, tissue morphology and particle transport in a biological milieu. The project is expected to benefit the advanced manufacturing, veterinary and medical sectors and could lead to new chemotherapeutics.Read moreRead less
Discovery Early Career Researcher Award - Grant ID: DE130100488
Funder
Australian Research Council
Funding Amount
$375,000.00
Summary
Cellular dynamics of nanoengineered particles. Nanotechnology has the capacity to drive a new wave of biological innovation through engineering materials at the nanoscale. This project will advance understanding of how nanoengineered materials interact with biological systems to enable the development of nanomaterials for future translational research.
Light-responsive nanomaterials as nanomedicines: new approaches to treating macular degeneration, cancer and other critical unmet therapeutic needs. Nanotechnology is enabling new medicines for the treatment of important diseases such as cancer and macular degeneration. This project will investigate novel nanomaterials for the development of new highly effective medicines that can be controlled after administration, leading to reduced side effects and increased convenience for patients.